This trial is evaluating whether CPI-300 will improve 1 primary outcome and 4 secondary outcomes in patients with Advanced Tumors. Measurement will happen over the course of 8 Days.
This trial requires 17 total participants across 2 different treatment groups
This trial involves 2 different treatments. CPI-300 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
More than 700,000 people die annually from the five most common types of cancer. Approximately half of these deaths occur among 30-year-olds and young adults.
Findings from a recent study provided no clear evidence that cisplatin plus apiculine plus capecitabine was more effective than cisplatin plus placebo plus capecitabine in patients with advanced solid tumors. There was also no proof that apiculine increased the efficacy of cisplatin-based treatment. Apiculine should not be considered as a treatment option when cisplatin-based regimens are being used in these patients.
Results from a recent clinical trial clearly shows a relationship between advanced tumors, and the immune-regulatory mechanisms known to be implicated in the development of cancer, suggesting that tumors may be perceived in an immune-responsive fashion by the host.
The following medical conditions exist as the first manifestation of cancer, other than lung cancer: benign lung disease, bronchiectasis, asbestosis, or asbestos exposure. The following medical conditions are found in 5% or more of the entire population and may have lung cancer as their first manifestation: pulmonary fibrosis, pneumoconiosis, pulmonary tuberculosis, asbestosis, pleural mesothelioma, and carcinoid syndrome. The last disease, carcinoid syndrome, is primarily associated with the appendix. When found, lung cancer often coexists with another cancer at occurrence time of more than 90% of lung cancers. In most cases, these coexisting cancers are concurrently detected or occur following diagnosis of lung cancer.
There is a higher cure rate for advanced tumors, compared with superficial tumors. Lymphatic invasion, extrapulmonary spread, or a high grade does not have any significant impact in the ability to cure advanced tumors. In the future, chemotherapy before surgery and radiation will have a greater impact on the success of cure for advanced tumors.
Signs of advanced tumors involve the lymph nodes. These can include pain or tenderness, as the tumor is growing within the lymph nodes, and can be felt or seen on inspection of the skin. Tumor size is not always correlated to lymph node size, but lymph node size can be an indicator of the size of the primary tumor. Tumor size may be assessed by obtaining a CT or MRI scan, or by biopsy, and its presence is often correlated to other signs of advanced tumors.
There are many common treatments for advanced cancers of the breast, liver, brain, skin, colon, and other organs. Cancer treatment can be a painful and debilitating process that is heavily relied on by patients and their families.
Cpi-300 is a potent inhibitor of the proliferation of some tumor cells. However, in clinical practice Cpi-300 has been used for several indications (e.g. advanced metastatic breast cancer, advanced colorectal cancer), as a single agent and without major side effects. Therefore, a large Phase III trial will hopefully be initiated in order to further investigate Cpi-300 usefulness, especially as monotherapy or in combination therapy.
There are multiple possible primary causes for advanced tumors, including local recurrence, distant metastasis, and acquired second primary tumors. A careful examination of all tumor types is critical for identifying the precise cause for an advanced tumor and, ultimately, for establishing appropriate prognosis and treatment.
Advanced tumors pose a greater threat than early tumors as long as they have metastasized before diagnosis or chemotherapy. Survival depends on local treatment. Larger tumors usually respond better to local treatment compared to small, small middle tumors. Larger tumors usually require more frequent local treatments which also have the benefit of greater improvement in overall survival.
There was no significant change in outcome between chemotherapy with CBT-300 and chemotherapy with CBT-100 when treatment was given in combination with another treatment (radiation plus chemotherapy versus radiotherapy plus hypertonic saline plus chemotherapy). The same information could be found in this study: (1) CBT-300 (compared to the control CBT-200) alone had a small impact on objective improvement; (2) hypertonic saline and chemotherapy did not improve objective benefit; and (3) radiotherapy plus conventional chemotherapy or radiotherapy alone provided no benefit compared to the control.
For people with a variety of cancer types, treatment with Cpi-300 appears to be safe. In particular, Cpi-300 appears to be safe for patients with bone and soft tissue tumors as well as cancers of the lung and colon. On the contrary, Cpi-300 does not seem to be safe for use in people with breast, pancreatic or kidney cancer. The safety of Cpi-300 is similar to that in patients treated with other chemotherapeutic agents and other immune-stimulating peptides. Given the limited data available at this time, further investigations seem warranted to clarify the safety of Cpi-300 for cancer patients.